← Back to Clinical Trials
Recruiting NCT06512441

Vitamin B6 Aids in Treating Inflammatory Bowel Disease

Trial Parameters

Condition Inflammatory Bowel Diseases
Sponsor Changhai Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 220
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2024-06-01
Completion 2025-12-30
Interventions
Vitamin B6 TabletsPlacebo

Brief Summary

Patients with IBD are randomized to oral administration of VitaminB6 and placebo based on the standard treatment, exploring whether VitaminB6 can increasee the clinical remission rateand improve the treatment effect of IBD patients.

Eligibility Criteria

Inclusion Criteria: * Patients diagnosed with IBD according to the consensus on the diagnosis and treatment of inflammatory bowel disease (Beijing, 2018, DOI: 10.19538/j.nk2018090106); * Have complete medical history data; * Volunteer to participate in this clinical trial and sign the informed consent form. Exclusion Criteria: * Patients with peripheral neuropathy; * Patients with abdominal abscess, toxic megacolon, fulminant colitis, partial colectomy, or total colectomy; * Patients with other autoimmune diseases, hematologic disorders, tumors, acute infections, severe liver or kidney dysfunction, severe conditions such as severe anemia, neutropenia, heart failure, organic heart disease, hepatitis B, cirrhosis, kidney disease, and psychiatric disorders; * Patients who have taken vitamin B6 tablets in the past 3 months; * Patients with a history of substance abuse; * Pregnant or lactating women, or those planning to become pregnant within the next 6 months; * Neurological disorders suc

Related Trials